144 related articles for article (PubMed ID: 16882549)
21. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.
Zhang C; Kwan P; Zuo Z; Baum L
Life Sci; 2010 Jun; 86(23-24):899-905. PubMed ID: 20417647
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
24. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1192-9. PubMed ID: 12948017
[TBL] [Abstract][Full Text] [Related]
25. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
26. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
27. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine.
Chae HW; Kim IW; Jin HE; Kim DD; Chung SJ; Shim CK
Arch Pharm Res; 2008 Jan; 31(1):103-10. PubMed ID: 18277615
[TBL] [Abstract][Full Text] [Related]
28. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
Störmer E; von Moltke LL; Perloff MD; Greenblatt DJ
Pharm Res; 2002 Jul; 19(7):1038-45. PubMed ID: 12180537
[TBL] [Abstract][Full Text] [Related]
29. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Störmer E; von Moltke LL; Perloff MD; Greenblatt DJ
J Clin Pharmacol; 2001 Jul; 41(7):708-14. PubMed ID: 11452702
[TBL] [Abstract][Full Text] [Related]
31. Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.
Patel J; Pal D; Vangal V; Gandhi M; Mitra AL
Pharm Res; 2002 Nov; 19(11):1696-703. PubMed ID: 12458676
[TBL] [Abstract][Full Text] [Related]
32. Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model.
Hu M; Chen J
Mol Pharm; 2004; 1(3):194-200. PubMed ID: 15981922
[TBL] [Abstract][Full Text] [Related]
33. Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.
Crowe A; Wong P
Toxicol Appl Pharmacol; 2003 Nov; 193(1):127-37. PubMed ID: 14613723
[TBL] [Abstract][Full Text] [Related]
34. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
35. Transepithelial transport of Cerulenin across Caco-2 cell monolayers.
Fu DH; Liu ZL; Liu JS; Luo Y; Shu Y; Huang SH; Han ZM
Eur J Drug Metab Pharmacokinet; 2009; 34(2):67-72. PubMed ID: 19645214
[TBL] [Abstract][Full Text] [Related]
36. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
37. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
38. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
39.
Jiang B; Yan LJ; Wu Q
DNA Cell Biol; 2019 May; 38(5):485-490. PubMed ID: 30977678
[TBL] [Abstract][Full Text] [Related]
40. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
